Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Therapeutics has released positive phase II trial data for Trisenox, which induced a high rate of responses in patients with late-stage relapsed or refractory multiple myeloma.
Subscribe to our email newsletter
Data from a multicenter, phase II trial of a Trisenox (arsenic trioxide) combination regimen, known as MAC (melphalan, Trisenox and vitamin C), were presented by Dr James Berenson, medical and scientific director of the Institute for Myeloma & Bone Cancer Research, at the tenth International Myeloma Workshop in Syndney, Australia.
The data showed that 60% of the patients evaluated achieved an objective response, with eight patients experiencing a decrease in serum M-protein of 50% or more and 14 patients experiencing a decrease in serum M-protein of between 25 to 49%.
Of the 29 patients who had failed prior thalidomide or lenolinamide therapy, 14 patients responded to the Trisenox regimen. In addition, seven out of ten patients who had failed bortezomib (Millennium Pharmaceutical’s Velcade) therapy responded and ten out of 16 patients who had received prior melphalan (GlaxoSmithKline’s Alkeran) therapy responded.
The study will continue to accrue to a target enrollment of 60 evaluable patients.